AbbVie Inc. closed 17.25% short of its 52-week high of $207.32, which the company achieved on October 31st.

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

UBS Group AG has removed Credit Suisse’s signs at its one-time arch-rival’s former headquarters in Zurich, replacing them ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

The simplified "H" forgoes the square frame found on the current logo and borrows a key element from its previous 60s-era ...

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...